DBV Financial Statements From 2010 to 2024
| DBV Stock | EUR 0.51 0.02 3.77% |
Check DBV Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DBV Technologies' main balance sheet or income statement drivers, such as , as well as many indicators such as . DBV financial statements analysis is a perfect complement when working with DBV Technologies Valuation or Volatility modules.
DBV |
DBV Technologies SA Company Current Valuation Analysis
DBV Technologies' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current DBV Technologies Current Valuation | 51.36 M |
Most of DBV Technologies' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DBV Technologies SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, DBV Technologies SA has a Current Valuation of 51.36 M. This is 99.64% lower than that of the Biotechnology sector and 98.89% lower than that of the Health Care industry. The current valuation for all France stocks is 99.69% higher than that of the company.
DBV Technologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining DBV Technologies's current stock value. Our valuation model uses many indicators to compare DBV Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DBV Technologies competition to find correlations between indicators driving DBV Technologies's intrinsic value. More Info.DBV Technologies SA is rated # 4 in return on equity category among its peers. It also is rated # 4 in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value DBV Technologies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DBV Technologies' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About DBV Technologies Financial Statements
DBV Technologies stakeholders use historical fundamental indicators, such as DBV Technologies' revenue or net income, to determine how well the company is positioned to perform in the future. Although DBV Technologies investors may analyze each financial statement separately, they are all interrelated. For example, changes in DBV Technologies' assets and liabilities are reflected in the revenues and expenses on DBV Technologies' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in DBV Technologies SA. Please read more on our technical analysis and fundamental analysis pages.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. DBV TECHNOLOGIES operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 97 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in DBV Stock
DBV Technologies financial ratios help investors to determine whether DBV Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DBV with respect to the benefits of owning DBV Technologies security.